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CASE REPORTS
CASE REPORT
A 32-year-old man who was previously healthy had a
1-week history of increasing abdominal pain, nausea, and
distention. A physical examination was significant for
abdominal distension without tenderness, hypoactive
bowel sounds, guaiac-positive stools, and normal periph-
eral pulses. Metabolic acidosis was not revealed by means
of laboratory studies; however, the white blood cell count
was elevated at 22,000 (normal, 4000 to 11,000), with a
left shift. Lack of flow in the portal vein was shown by
means of a Doppler ultrasound scanning examination.
Portal vein, splenic vein, and diffuse superior mesenteric
vein (SMV) thrombosis was demonstrated by means of an
abdominal computed tomography (CT) scan. The small
bowel was diffusely dilated and thickened, and a small
amount of ascites was present (Fig 1). The patient had no
past personal or family history of thrombotic events.
Intravenous heparin was initiated, and some melenic
stools developed in the patient, who required a transfusion
of 3 units of blood. The patient remained hemodynami-
cally stable during this time.
Because of a previous report,2 we thought that antico-
agulation with heparin and concomitant superior mesen-
teric artery thrombolytic therapy with urokinase was the
best course, with transfusion support if there was ongoing
gastrointestinal (GI) bleeding. The GI bleeding was
thought to be caused by diffuse mucosal ischemia and
slough related to venous congestion and diffuse small
bowel edema. We thought that the GI bleeding was self-
limited and thrombolytic therapy should still be tried.
The patient underwent right femoral artery cannula-
tion, and a 5F Cook catheter (Cook, Bloomington, Ind)
was advanced into the superior mesenteric artery (SMA).
Delayed images showed no flow in the portal, splenic, or
superior mesenteric veins, with a few small splenic and
periportal venous collaterals (Fig 2). Urokinase was
infused at 240,000 U/h for 2 hours, and then continued
at 100,000 U/h for the next 4 days. Heparin infusion was
maintained at therapeutic levels of two times the control
throughout therapy. Progressive increase in portal and
mesenteric flow was shown by means of daily repeated
angiography (Fig 3). The catheter was removed on the
fifth day of hospitalization. There was no further GI
bleeding or transfusion administered after the initiation of
urokinase. On completion of the urokinase infusion, the
patient was continued on heparin. Normal directional flow
in the portal and splenic veins was demonstrated by means
of ultrasound scanning. On day 6 of hospitalization, war-
farin was initiated, and heparin was stopped when a thera-
peutic level was achieved.
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Extensive laboratory testing for a primary hypercoag-
ulable state was performed on admission. Testing includ-
ed: assay for factor V-Leiden mutation; antithrombin III
and protein C and S levels; antiphospholipid antibody;
anticardiolipin antibody; tests for collagen vascular disease;
factor II level; plasma homocysteine level; and screen for
paroxysmal nocturnal hemoglobinuria. All tests were nor-
mal (including the factor V gene), with the exception of a
low protein S level, which was 54% of normal. 
The patient was discharged on the ninth day of hospi-
talization, taking warfarin and tolerating a regular diet. At
a follow-up examination 8 months later, the patient was
doing well and tolerating a regular diet; he will remain on
lifelong anticoagulation with warfarin. 
DISCUSSION
Mesenteric venous thrombosis is a rare but life-
threatening disease. Traditional surgical treatment of
this disease centered around early diagnosis and oper-
ation with resection of nonviable bowel. It is often
difficult to distinguish viable and nonviable bowel
because of the diffuse edema and venous congestion,
and second-look procedures are frequently recom-
mended.1 This approach is uniformly unsatisfying and
associated with high mortality (30% to 50%) and
recurrence rates (10% to 30%).1 Thrombolytic thera-
py for mesenteric venous thrombosis is a novel alter-
native treatment approach that may allow surgery to
be reserved for patients with the complication of
bowel infarction with peritonitis or patients who can-
not receive thrombolytics. Historically, the standard
approach to a patient with SMV thrombosis and
ascites would be operative exploration. We thought
that this patient was hemodynamically stable, without
the presence of metabolic acidosis or significant
abdominal tenderness, and would be a good candi-
date for nonoperative treatment with thrombolytics.
The ascites noted by means of the abdominal CT scan
was felt to be a result of acute portal venous hyper-
tension and diffuse bowel edema and not an indicator
of bowel injury requiring operation. The GI bleeding
was thought to be an initial self-limited event related
to mucosal slough and was not considered to be an
absolute contraindication to thrombolytic therapy.
Superior mesenteric artery urokinase infusion
avoids the risks of a transhepatic approach. Our
report extends the time of infusion to 96 hours
without complications. The duration of thrombolyt-
ic therapy can be variable, but complications increase
with the length of time of infusion.4 Although there
was still a small amount of residual thrombus after
96 hours of urokinase infusion, the acute portal
venous hypertension had been reversed, and the
patient was clinically improved. There is no estab-
lished guideline other than clinical judgment for the
end point of thrombolytic therapy at this time.
Risk factors for venous thrombosis include hyper-
coagulable states, portal hypertension, trauma, post-
splenectomy, malignancy, inflammatory states, preg-
nancy, and oral contraceptive use.6-9 In young
patients who do not have known risk factors for
thrombosis, a thorough workup for a primary hyper-
coagulable state is warranted. Overall, the most com-
mon cause is myeloproliferative disease. Other causes
include genetic factors such as: factor V Leiden muta-
tion (activated protein C resistance); antithrombin
III deficiency; protein C or S deficiency or resistance;
factor II deficiency; plasma hyperhomocystinemia;
paroxysmal nocturnal hemoglobinuria; or acquired
risk factors such as antiphospholipid antibody or anti-
cardiolipin antibody syndromes, collagen vascular
disease, or dysfibrinogenemia.6-9 Therapy is tailored
to the specific disorder; however, when a significant
thrombotic event occurs, lifelong anticoagulation
with warfarin is usually necessary. 
Genetic factors have recently been recognized as
important causes of venous thrombosis. The factor
V Leiden mutation is the most common cause of
inherited venous thrombosis (usually lower-extremi-
ty deep venous thrombosis). Protein S is a plasma
protein that acts as a co-factor to protein C, which
inhibits coagulation by proteolytically inactivating
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Fig 1. Computed tomography scan showing clot in the
superior mesenteric vein (arrow) with some surrounding
contrast enhancement. Also seen is a loop of dilated and
markedly thickened small bowel. This process was noted to
involve the entire small bowel on other images.
factors V and VIII.6 Protein S deficiency is rare,
accounting for less than 5% of the inherited throm-
botic disorders, and is almost exclusively associated
with venous, rather than arterial, thrombosis. In
39% of patients who are protein S deficient and who
have a thrombotic event, there is an associated
genetic risk factor of the factor V Leiden mutation.7
Because this patient had known protein S defi-
ciency, heparin was continued during the initiation
of warfarin anticoagulation to avoid complications
related to an initial paradoxical hypercoagulable
state (warfarin-induced skin necrosis). Only after
achieving a therapeutic prothrombin with warfarin
was the heparin discontinued.
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Fig 2. Venous phase of a superior mesenteric arteriogram showing extensive portal vein
thrombosis. Some flow is seen in periportal collateral vessels (arrow).
Fig 3. Venous phase of a superior mesenteric arteriogram on the fifth day of urokinase infu-
sion demonstrating marked improvement in portal venous flow. There is a small amount of
nonocclusive residual thrombus noted in the main and left portal vein (arrow).
An awareness of these genetic and acquired hyper-
coagulable states is needed to properly diagnose the
condition and treat these patients. Nonoperative
treatment of this unusual problem with the use of
thrombolytic therapy should be considered.
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